The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Treating Mental Disorders Market Research Report 2024
Synopsis
The global Drugs for Treating Mental Disorders market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Treating Mental Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Treating Mental Disorders.
Report Scope
The Drugs for Treating Mental Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Treating Mental Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Treating Mental Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson and Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Teva Pharmaceutical
Dr. Reddy's Laboratories
Apotex Inc.
Mylan Pharmaceuticals
Par Pharmaceutical
Aurobindo Pharma
Torrent Pharmaceuticals
Jubilant Lifesciences
Sun Pharmaceutical
Sandoz (Novartis)
Hansoh Pharmaceutical
WATSON Pharmaceuticals
Zhejiang Langhua Pharmaceuticals
Forest Laboratories
H.Lundbeck A/S
Amneal Pharmaceuticals
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Hikma Pharmaceuticals
Lupin Limited
Prinston Pharmaceutical
STI Pharma
Segment by Type
Tablets
Capsule
Injection
Solution
Other
Segment by Application
Antipsychotics
Antidepressants
Antianxiety (Anxiolyitcs)
Anti-Seizure Medications
Stimulants
Cognitive Disorders And Dementia
Sleep Disorder Treatments
Substance Abuse Treatments
Hypnosis And Tranquilizers
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Treating Mental Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Drugs for Treating Mental Disorders market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Treating Mental Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Treating Mental Disorders.
Report Scope
The Drugs for Treating Mental Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Treating Mental Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Treating Mental Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson and Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Teva Pharmaceutical
Dr. Reddy's Laboratories
Apotex Inc.
Mylan Pharmaceuticals
Par Pharmaceutical
Aurobindo Pharma
Torrent Pharmaceuticals
Jubilant Lifesciences
Sun Pharmaceutical
Sandoz (Novartis)
Hansoh Pharmaceutical
WATSON Pharmaceuticals
Zhejiang Langhua Pharmaceuticals
Forest Laboratories
H.Lundbeck A/S
Amneal Pharmaceuticals
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Hikma Pharmaceuticals
Lupin Limited
Prinston Pharmaceutical
STI Pharma
Segment by Type
Tablets
Capsule
Injection
Solution
Other
Segment by Application
Antipsychotics
Antidepressants
Antianxiety (Anxiolyitcs)
Anti-Seizure Medications
Stimulants
Cognitive Disorders And Dementia
Sleep Disorder Treatments
Substance Abuse Treatments
Hypnosis And Tranquilizers
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Treating Mental Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Treating Mental Disorders Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tablets
1.2.3 Capsule
1.2.4 Injection
1.2.5 Solution
1.2.6 Other
1.3 Market by Application
1.3.1 Global Drugs for Treating Mental Disorders Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Antipsychotics
1.3.3 Antidepressants
1.3.4 Antianxiety (Anxiolyitcs)
1.3.5 Anti-Seizure Medications
1.3.6 Stimulants
1.3.7 Cognitive Disorders And Dementia
1.3.8 Sleep Disorder Treatments
1.3.9 Substance Abuse Treatments
1.3.10 Hypnosis And Tranquilizers
1.3.11 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Treating Mental Disorders Market Perspective (2019-2030)
2.2 Drugs for Treating Mental Disorders Growth Trends by Region
2.2.1 Global Drugs for Treating Mental Disorders Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Treating Mental Disorders Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Treating Mental Disorders Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Treating Mental Disorders Market Dynamics
2.3.1 Drugs for Treating Mental Disorders Industry Trends
2.3.2 Drugs for Treating Mental Disorders Market Drivers
2.3.3 Drugs for Treating Mental Disorders Market Challenges
2.3.4 Drugs for Treating Mental Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Treating Mental Disorders Players by Revenue
3.1.1 Global Top Drugs for Treating Mental Disorders Players by Revenue (2019-2024)
3.1.2 Global Drugs for Treating Mental Disorders Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Treating Mental Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Treating Mental Disorders Revenue
3.4 Global Drugs for Treating Mental Disorders Market Concentration Ratio
3.4.1 Global Drugs for Treating Mental Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Treating Mental Disorders Revenue in 2023
3.5 Drugs for Treating Mental Disorders Key Players Head office and Area Served
3.6 Key Players Drugs for Treating Mental Disorders Product Solution and Service
3.7 Date of Enter into Drugs for Treating Mental Disorders Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Treating Mental Disorders Breakdown Data by Type
4.1 Global Drugs for Treating Mental Disorders Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Treating Mental Disorders Forecasted Market Size by Type (2025-2030)
5 Drugs for Treating Mental Disorders Breakdown Data by Application
5.1 Global Drugs for Treating Mental Disorders Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Treating Mental Disorders Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Treating Mental Disorders Market Size (2019-2030)
6.2 North America Drugs for Treating Mental Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Treating Mental Disorders Market Size by Country (2019-2024)
6.4 North America Drugs for Treating Mental Disorders Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Treating Mental Disorders Market Size (2019-2030)
7.2 Europe Drugs for Treating Mental Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Treating Mental Disorders Market Size by Country (2019-2024)
7.4 Europe Drugs for Treating Mental Disorders Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Treating Mental Disorders Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Treating Mental Disorders Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Treating Mental Disorders Market Size (2019-2030)
9.2 Latin America Drugs for Treating Mental Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Treating Mental Disorders Market Size by Country (2019-2024)
9.4 Latin America Drugs for Treating Mental Disorders Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Treating Mental Disorders Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Treating Mental Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson and Johnson
11.1.1 Johnson and Johnson Company Detail
11.1.2 Johnson and Johnson Business Overview
11.1.3 Johnson and Johnson Drugs for Treating Mental Disorders Introduction
11.1.4 Johnson and Johnson Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.1.5 Johnson and Johnson Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Drugs for Treating Mental Disorders Introduction
11.2.4 Pfizer Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Drugs for Treating Mental Disorders Introduction
11.3.4 Eli Lilly Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Drugs for Treating Mental Disorders Introduction
11.4.4 GlaxoSmithKline Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Drugs for Treating Mental Disorders Introduction
11.5.4 AstraZeneca Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Drugs for Treating Mental Disorders Introduction
11.6.4 Bristol-Myers Squibb Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Detail
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Drugs for Treating Mental Disorders Introduction
11.7.4 Teva Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.7.5 Teva Pharmaceutical Recent Development
11.8 Dr. Reddy's Laboratories
11.8.1 Dr. Reddy's Laboratories Company Detail
11.8.2 Dr. Reddy's Laboratories Business Overview
11.8.3 Dr. Reddy's Laboratories Drugs for Treating Mental Disorders Introduction
11.8.4 Dr. Reddy's Laboratories Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.8.5 Dr. Reddy's Laboratories Recent Development
11.9 Apotex Inc.
11.9.1 Apotex Inc. Company Detail
11.9.2 Apotex Inc. Business Overview
11.9.3 Apotex Inc. Drugs for Treating Mental Disorders Introduction
11.9.4 Apotex Inc. Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.9.5 Apotex Inc. Recent Development
11.10 Mylan Pharmaceuticals
11.10.1 Mylan Pharmaceuticals Company Detail
11.10.2 Mylan Pharmaceuticals Business Overview
11.10.3 Mylan Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.10.4 Mylan Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.10.5 Mylan Pharmaceuticals Recent Development
11.11 Par Pharmaceutical
11.11.1 Par Pharmaceutical Company Detail
11.11.2 Par Pharmaceutical Business Overview
11.11.3 Par Pharmaceutical Drugs for Treating Mental Disorders Introduction
11.11.4 Par Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.11.5 Par Pharmaceutical Recent Development
11.12 Aurobindo Pharma
11.12.1 Aurobindo Pharma Company Detail
11.12.2 Aurobindo Pharma Business Overview
11.12.3 Aurobindo Pharma Drugs for Treating Mental Disorders Introduction
11.12.4 Aurobindo Pharma Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.12.5 Aurobindo Pharma Recent Development
11.13 Torrent Pharmaceuticals
11.13.1 Torrent Pharmaceuticals Company Detail
11.13.2 Torrent Pharmaceuticals Business Overview
11.13.3 Torrent Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.13.4 Torrent Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.13.5 Torrent Pharmaceuticals Recent Development
11.14 Jubilant Lifesciences
11.14.1 Jubilant Lifesciences Company Detail
11.14.2 Jubilant Lifesciences Business Overview
11.14.3 Jubilant Lifesciences Drugs for Treating Mental Disorders Introduction
11.14.4 Jubilant Lifesciences Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.14.5 Jubilant Lifesciences Recent Development
11.15 Sun Pharmaceutical
11.15.1 Sun Pharmaceutical Company Detail
11.15.2 Sun Pharmaceutical Business Overview
11.15.3 Sun Pharmaceutical Drugs for Treating Mental Disorders Introduction
11.15.4 Sun Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.15.5 Sun Pharmaceutical Recent Development
11.16 Sandoz (Novartis)
11.16.1 Sandoz (Novartis) Company Detail
11.16.2 Sandoz (Novartis) Business Overview
11.16.3 Sandoz (Novartis) Drugs for Treating Mental Disorders Introduction
11.16.4 Sandoz (Novartis) Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.16.5 Sandoz (Novartis) Recent Development
11.17 Hansoh Pharmaceutical
11.17.1 Hansoh Pharmaceutical Company Detail
11.17.2 Hansoh Pharmaceutical Business Overview
11.17.3 Hansoh Pharmaceutical Drugs for Treating Mental Disorders Introduction
11.17.4 Hansoh Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.17.5 Hansoh Pharmaceutical Recent Development
11.18 WATSON Pharmaceuticals
11.18.1 WATSON Pharmaceuticals Company Detail
11.18.2 WATSON Pharmaceuticals Business Overview
11.18.3 WATSON Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.18.4 WATSON Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.18.5 WATSON Pharmaceuticals Recent Development
11.19 Zhejiang Langhua Pharmaceuticals
11.19.1 Zhejiang Langhua Pharmaceuticals Company Detail
11.19.2 Zhejiang Langhua Pharmaceuticals Business Overview
11.19.3 Zhejiang Langhua Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.19.4 Zhejiang Langhua Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.19.5 Zhejiang Langhua Pharmaceuticals Recent Development
11.20 Forest Laboratories
11.20.1 Forest Laboratories Company Detail
11.20.2 Forest Laboratories Business Overview
11.20.3 Forest Laboratories Drugs for Treating Mental Disorders Introduction
11.20.4 Forest Laboratories Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.20.5 Forest Laboratories Recent Development
11.21 H.Lundbeck A/S
11.21.1 H.Lundbeck A/S Company Detail
11.21.2 H.Lundbeck A/S Business Overview
11.21.3 H.Lundbeck A/S Drugs for Treating Mental Disorders Introduction
11.21.4 H.Lundbeck A/S Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.21.5 H.Lundbeck A/S Recent Development
11.22 Amneal Pharmaceuticals
11.22.1 Amneal Pharmaceuticals Company Detail
11.22.2 Amneal Pharmaceuticals Business Overview
11.22.3 Amneal Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.22.4 Amneal Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.22.5 Amneal Pharmaceuticals Recent Development
11.23 Hetero Drugs
11.23.1 Hetero Drugs Company Detail
11.23.2 Hetero Drugs Business Overview
11.23.3 Hetero Drugs Drugs for Treating Mental Disorders Introduction
11.23.4 Hetero Drugs Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.23.5 Hetero Drugs Recent Development
11.24 Macleods Pharmaceuticals
11.24.1 Macleods Pharmaceuticals Company Detail
11.24.2 Macleods Pharmaceuticals Business Overview
11.24.3 Macleods Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.24.4 Macleods Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.24.5 Macleods Pharmaceuticals Recent Development
11.25 Silarx Pharmacueticals
11.25.1 Silarx Pharmacueticals Company Detail
11.25.2 Silarx Pharmacueticals Business Overview
11.25.3 Silarx Pharmacueticals Drugs for Treating Mental Disorders Introduction
11.25.4 Silarx Pharmacueticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.25.5 Silarx Pharmacueticals Recent Development
11.26 Hikma Pharmaceuticals
11.26.1 Hikma Pharmaceuticals Company Detail
11.26.2 Hikma Pharmaceuticals Business Overview
11.26.3 Hikma Pharmaceuticals Drugs for Treating Mental Disorders Introduction
11.26.4 Hikma Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.26.5 Hikma Pharmaceuticals Recent Development
11.27 Lupin Limited
11.27.1 Lupin Limited Company Detail
11.27.2 Lupin Limited Business Overview
11.27.3 Lupin Limited Drugs for Treating Mental Disorders Introduction
11.27.4 Lupin Limited Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.27.5 Lupin Limited Recent Development
11.28 Prinston Pharmaceutical
11.28.1 Prinston Pharmaceutical Company Detail
11.28.2 Prinston Pharmaceutical Business Overview
11.28.3 Prinston Pharmaceutical Drugs for Treating Mental Disorders Introduction
11.28.4 Prinston Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.28.5 Prinston Pharmaceutical Recent Development
11.29 STI Pharma
11.29.1 STI Pharma Company Detail
11.29.2 STI Pharma Business Overview
11.29.3 STI Pharma Drugs for Treating Mental Disorders Introduction
11.29.4 STI Pharma Revenue in Drugs for Treating Mental Disorders Business (2019-2024)
11.29.5 STI Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Drugs for Treating Mental Disorders Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tablets
Table 3. Key Players of Capsule
Table 4. Key Players of Injection
Table 5. Key Players of Solution
Table 6. Key Players of Other
Table 7. Global Drugs for Treating Mental Disorders Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Drugs for Treating Mental Disorders Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Drugs for Treating Mental Disorders Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Drugs for Treating Mental Disorders Market Share by Region (2019-2024)
Table 11. Global Drugs for Treating Mental Disorders Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Drugs for Treating Mental Disorders Market Share by Region (2025-2030)
Table 13. Drugs for Treating Mental Disorders Market Trends
Table 14. Drugs for Treating Mental Disorders Market Drivers
Table 15. Drugs for Treating Mental Disorders Market Challenges
Table 16. Drugs for Treating Mental Disorders Market Restraints
Table 17. Global Drugs for Treating Mental Disorders Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Drugs for Treating Mental Disorders Market Share by Players (2019-2024)
Table 19. Global Top Drugs for Treating Mental Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Mental Disorders as of 2023)
Table 20. Ranking of Global Top Drugs for Treating Mental Disorders Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Drugs for Treating Mental Disorders Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Treating Mental Disorders Product Solution and Service
Table 24. Date of Enter into Drugs for Treating Mental Disorders Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Treating Mental Disorders Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Drugs for Treating Mental Disorders Revenue Market Share by Type (2019-2024)
Table 28. Global Drugs for Treating Mental Disorders Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Drugs for Treating Mental Disorders Revenue Market Share by Type (2025-2030)
Table 30. Global Drugs for Treating Mental Disorders Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Drugs for Treating Mental Disorders Revenue Market Share by Application (2019-2024)
Table 32. Global Drugs for Treating Mental Disorders Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Drugs for Treating Mental Disorders Revenue Market Share by Application (2025-2030)
Table 34. North America Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Drugs for Treating Mental Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Drugs for Treating Mental Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Drugs for Treating Mental Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Drugs for Treating Mental Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Drugs for Treating Mental Disorders Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Drugs for Treating Mental Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Drugs for Treating Mental Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 49. Johnson and Johnson Company Detail
Table 50. Johnson and Johnson Business Overview
Table 51. Johnson and Johnson Drugs for Treating Mental Disorders Product
Table 52. Johnson and Johnson Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 53. Johnson and Johnson Recent Development
Table 54. Pfizer Company Detail
Table 55. Pfizer Business Overview
Table 56. Pfizer Drugs for Treating Mental Disorders Product
Table 57. Pfizer Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 58. Pfizer Recent Development
Table 59. Eli Lilly Company Detail
Table 60. Eli Lilly Business Overview
Table 61. Eli Lilly Drugs for Treating Mental Disorders Product
Table 62. Eli Lilly Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 63. Eli Lilly Recent Development
Table 64. GlaxoSmithKline Company Detail
Table 65. GlaxoSmithKline Business Overview
Table 66. GlaxoSmithKline Drugs for Treating Mental Disorders Product
Table 67. GlaxoSmithKline Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 68. GlaxoSmithKline Recent Development
Table 69. AstraZeneca Company Detail
Table 70. AstraZeneca Business Overview
Table 71. AstraZeneca Drugs for Treating Mental Disorders Product
Table 72. AstraZeneca Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 73. AstraZeneca Recent Development
Table 74. Bristol-Myers Squibb Company Detail
Table 75. Bristol-Myers Squibb Business Overview
Table 76. Bristol-Myers Squibb Drugs for Treating Mental Disorders Product
Table 77. Bristol-Myers Squibb Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Teva Pharmaceutical Company Detail
Table 80. Teva Pharmaceutical Business Overview
Table 81. Teva Pharmaceutical Drugs for Treating Mental Disorders Product
Table 82. Teva Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 83. Teva Pharmaceutical Recent Development
Table 84. Dr. Reddy's Laboratories Company Detail
Table 85. Dr. Reddy's Laboratories Business Overview
Table 86. Dr. Reddy's Laboratories Drugs for Treating Mental Disorders Product
Table 87. Dr. Reddy's Laboratories Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 88. Dr. Reddy's Laboratories Recent Development
Table 89. Apotex Inc. Company Detail
Table 90. Apotex Inc. Business Overview
Table 91. Apotex Inc. Drugs for Treating Mental Disorders Product
Table 92. Apotex Inc. Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 93. Apotex Inc. Recent Development
Table 94. Mylan Pharmaceuticals Company Detail
Table 95. Mylan Pharmaceuticals Business Overview
Table 96. Mylan Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 97. Mylan Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 98. Mylan Pharmaceuticals Recent Development
Table 99. Par Pharmaceutical Company Detail
Table 100. Par Pharmaceutical Business Overview
Table 101. Par Pharmaceutical Drugs for Treating Mental Disorders Product
Table 102. Par Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 103. Par Pharmaceutical Recent Development
Table 104. Aurobindo Pharma Company Detail
Table 105. Aurobindo Pharma Business Overview
Table 106. Aurobindo Pharma Drugs for Treating Mental Disorders Product
Table 107. Aurobindo Pharma Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 108. Aurobindo Pharma Recent Development
Table 109. Torrent Pharmaceuticals Company Detail
Table 110. Torrent Pharmaceuticals Business Overview
Table 111. Torrent Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 112. Torrent Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 113. Torrent Pharmaceuticals Recent Development
Table 114. Jubilant Lifesciences Company Detail
Table 115. Jubilant Lifesciences Business Overview
Table 116. Jubilant Lifesciences Drugs for Treating Mental Disorders Product
Table 117. Jubilant Lifesciences Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 118. Jubilant Lifesciences Recent Development
Table 119. Sun Pharmaceutical Company Detail
Table 120. Sun Pharmaceutical Business Overview
Table 121. Sun Pharmaceutical Drugs for Treating Mental Disorders Product
Table 122. Sun Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 123. Sun Pharmaceutical Recent Development
Table 124. Sandoz (Novartis) Company Detail
Table 125. Sandoz (Novartis) Business Overview
Table 126. Sandoz (Novartis) Drugs for Treating Mental Disorders Product
Table 127. Sandoz (Novartis) Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 128. Sandoz (Novartis) Recent Development
Table 129. Hansoh Pharmaceutical Company Detail
Table 130. Hansoh Pharmaceutical Business Overview
Table 131. Hansoh Pharmaceutical Drugs for Treating Mental Disorders Product
Table 132. Hansoh Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 133. Hansoh Pharmaceutical Recent Development
Table 134. WATSON Pharmaceuticals Company Detail
Table 135. WATSON Pharmaceuticals Business Overview
Table 136. WATSON Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 137. WATSON Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 138. WATSON Pharmaceuticals Recent Development
Table 139. Zhejiang Langhua Pharmaceuticals Company Detail
Table 140. Zhejiang Langhua Pharmaceuticals Business Overview
Table 141. Zhejiang Langhua Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 142. Zhejiang Langhua Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 143. Zhejiang Langhua Pharmaceuticals Recent Development
Table 144. Forest Laboratories Company Detail
Table 145. Forest Laboratories Business Overview
Table 146. Forest Laboratories Drugs for Treating Mental Disorders Product
Table 147. Forest Laboratories Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 148. Forest Laboratories Recent Development
Table 149. H.Lundbeck A/S Company Detail
Table 150. H.Lundbeck A/S Business Overview
Table 151. H.Lundbeck A/S Drugs for Treating Mental Disorders Product
Table 152. H.Lundbeck A/S Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 153. H.Lundbeck A/S Recent Development
Table 154. Amneal Pharmaceuticals Company Detail
Table 155. Amneal Pharmaceuticals Business Overview
Table 156. Amneal Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 157. Amneal Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 158. Amneal Pharmaceuticals Recent Development
Table 159. Hetero Drugs Company Detail
Table 160. Hetero Drugs Business Overview
Table 161. Hetero Drugs Drugs for Treating Mental Disorders Product
Table 162. Hetero Drugs Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 163. Hetero Drugs Recent Development
Table 164. Macleods Pharmaceuticals Company Detail
Table 165. Macleods Pharmaceuticals Business Overview
Table 166. Macleods Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 167. Macleods Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 168. Macleods Pharmaceuticals Recent Development
Table 169. Silarx Pharmacueticals Company Detail
Table 170. Silarx Pharmacueticals Business Overview
Table 171. Silarx Pharmacueticals Drugs for Treating Mental Disorders Product
Table 172. Silarx Pharmacueticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 173. Silarx Pharmacueticals Recent Development
Table 174. Hikma Pharmaceuticals Company Detail
Table 175. Hikma Pharmaceuticals Business Overview
Table 176. Hikma Pharmaceuticals Drugs for Treating Mental Disorders Product
Table 177. Hikma Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 178. Hikma Pharmaceuticals Recent Development
Table 179. Lupin Limited Company Detail
Table 180. Lupin Limited Business Overview
Table 181. Lupin Limited Drugs for Treating Mental Disorders Product
Table 182. Lupin Limited Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 183. Lupin Limited Recent Development
Table 184. Prinston Pharmaceutical Company Detail
Table 185. Prinston Pharmaceutical Business Overview
Table 186. Prinston Pharmaceutical Drugs for Treating Mental Disorders Product
Table 187. Prinston Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 188. Prinston Pharmaceutical Recent Development
Table 189. STI Pharma Company Detail
Table 190. STI Pharma Business Overview
Table 191. STI Pharma Drugs for Treating Mental Disorders Product
Table 192. STI Pharma Revenue in Drugs for Treating Mental Disorders Business (2019-2024) & (US$ Million)
Table 193. STI Pharma Recent Development
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Treating Mental Disorders Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Drugs for Treating Mental Disorders Market Share by Type: 2023 VS 2030
Figure 3. Tablets Features
Figure 4. Capsule Features
Figure 5. Injection Features
Figure 6. Solution Features
Figure 7. Other Features
Figure 8. Global Drugs for Treating Mental Disorders Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Drugs for Treating Mental Disorders Market Share by Application: 2023 VS 2030
Figure 10. Antipsychotics Case Studies
Figure 11. Antidepressants Case Studies
Figure 12. Antianxiety (Anxiolyitcs) Case Studies
Figure 13. Anti-Seizure Medications Case Studies
Figure 14. Stimulants Case Studies
Figure 15. Cognitive Disorders And Dementia Case Studies
Figure 16. Sleep Disorder Treatments Case Studies
Figure 17. Substance Abuse Treatments Case Studies
Figure 18. Hypnosis And Tranquilizers Case Studies
Figure 19. Other Case Studies
Figure 20. Drugs for Treating Mental Disorders Report Years Considered
Figure 21. Global Drugs for Treating Mental Disorders Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 22. Global Drugs for Treating Mental Disorders Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 23. Global Drugs for Treating Mental Disorders Market Share by Region: 2023 VS 2030
Figure 24. Global Drugs for Treating Mental Disorders Market Share by Players in 2023
Figure 25. Global Top Drugs for Treating Mental Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Mental Disorders as of 2023)
Figure 26. The Top 10 and 5 Players Market Share by Drugs for Treating Mental Disorders Revenue in 2023
Figure 27. North America Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. North America Drugs for Treating Mental Disorders Market Share by Country (2019-2030)
Figure 29. United States Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Canada Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Europe Drugs for Treating Mental Disorders Market Share by Country (2019-2030)
Figure 33. Germany Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. France Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. U.K. Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Italy Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Russia Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Nordic Countries Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Asia-Pacific Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Asia-Pacific Drugs for Treating Mental Disorders Market Share by Region (2019-2030)
Figure 41. China Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Japan Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. South Korea Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. India Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Australia Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Latin America Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Latin America Drugs for Treating Mental Disorders Market Share by Country (2019-2030)
Figure 49. Mexico Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Brazil Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Middle East & Africa Drugs for Treating Mental Disorders Market Share by Country (2019-2030)
Figure 53. Turkey Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Drugs for Treating Mental Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Johnson and Johnson Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 56. Pfizer Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 57. Eli Lilly Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 58. GlaxoSmithKline Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 59. AstraZeneca Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 61. Teva Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 62. Dr. Reddy's Laboratories Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 63. Apotex Inc. Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 64. Mylan Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 65. Par Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 66. Aurobindo Pharma Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 67. Torrent Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 68. Jubilant Lifesciences Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 69. Sun Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 70. Sandoz (Novartis) Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 71. Hansoh Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 72. WATSON Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 73. Zhejiang Langhua Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 74. Forest Laboratories Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 75. H.Lundbeck A/S Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 76. Amneal Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 77. Hetero Drugs Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 78. Macleods Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 79. Silarx Pharmacueticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 80. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 81. Lupin Limited Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 82. Prinston Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 83. STI Pharma Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2019-2024)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
